Results 21 to 30 of about 340,090 (253)

In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus

Viruses, 2020
Influenza A virus, one of the major human respiratory pathogens, is responsible for annual seasonal endemics and unpredictable periodic pandemics. Despite the clinical availability of vaccines and antivirals, the antigenic diversity and drug resistance ...
Yejin Jang, Jin Soo Shin, Joo-Youn Lee, Heegwon Shin, Sang Jick Kim, Meehyein Kim   +5 more
doaj   +1 more source

HIV-1 gp41 Fusion Intermediate: A Target for HIV Therapeutics

Journal of the Formosan Medical Association, 2010
Human immunodeficiency virus (HIV)-1 infection is initiated by the binding of gp120 envelope glyco-protein to its cell receptor (CD4) and a coreceptor (CXCR4 or CCR5), followed by a series of conformational changes in the gp41 transmembrane subunit ...
Chungen Pan, Shuwen Liu, Shibo Jiang
doaj   +1 more source

Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket

Frontiers in Cellular and Infection Microbiology, 2018
The deep hydrophobic pocket of HIV-1 gp41 has been considered a drug target, but short-peptides targeting this site usually lack potent antiviral activity.
Xiujuan Zhang, Xiujuan Zhang, Yuanmei Zhu, Hao Hu, Senyan Zhang, Pengfei Wang, Huihui Chong, Jinsheng He, Xinquan Wang, Yuxian He   +9 more
doaj   +1 more source

SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron

Emerging Microbes and Infections, 2022
The emergence of SARS-CoV-2 Omicron and other variants of concern (VOCs) has brought huge challenges to control the COVID-19 pandemic, calling for urgent development of effective vaccines and therapeutic drugs. In this study, we focused on characterizing
Yuanmei Zhu, Xiaojing Dong, Nian Liu, Tong Wu, Huihui Chong, Xiaobo Lei, Lili Ren, Jianwei Wang, Yuxian He   +8 more
doaj   +1 more source

SERINC5 Restricts HIV-1 Infectivity by Promoting Conformational Changes and Accelerating Functional Inactivation of Env

Viruses, 2022
SERINC5 incorporates into HIV-1 particles and inhibits the ability of Env glycoprotein to mediate virus-cell fusion. SERINC5-resistance maps to Env, with primary isolates generally showing greater resistance than laboratory-adapted strains.
Junghwa Kirschman, Mariana Marin, Yen-Cheng Chen, Junhua Chen, Alon Herschhorn, Amos B. Smith, Gregory B. Melikyan   +6 more
doaj   +1 more source

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

BMC Cancer, 2022
Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development
Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason   +8 more
doaj   +1 more source

Ginkgolic Acid Inhibits Coronavirus Strain 229E Infection of Human Epithelial Lung Cells

Pharmaceuticals, 2021
Since December 2019, the COVID-19 pandemic has affected more than 200 million individuals around the globe and caused millions of deaths. Although there are now multiple vaccines for SARS-CoV-2, their efficacy may be limited by current and future viral ...
Maimoona S. Bhutta, Daniel G. Sausen, Elisa S. Gallo, Harel Dahari, Gustavo F. Doncel, Ronen Borenstein   +5 more
doaj   +1 more source

Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern

mBio, 2022
The ability of SARS-CoV-2 to evolve in response to selective pressures poses a challenge to vaccine and antiviral efficacy. The S1 subunit of the spike (S) protein contains the receptor-binding domain and is therefore under selective pressure to evade ...
Katharina S. Schmitz, Daryl Geers, Rory D. de Vries, T. Francesca Bovier, Anna Z. Mykytyn, Corine H. Geurts van Kessel, Bart L. Haagmans, Matteo Porotto, Rik L. de Swart, Anne Moscona   +9 more
doaj   +1 more source

Fusion promoter or fusion inhibitor?

The Journal of Cell Biology, 2003
![Graphic][1] Cells in fusogenic conditions (right) have less, rather than more, CD9 (green).Mononuclear phagocytes can fuse to form osteoclasts or multinuclear giant cells. The latter are hallmarks of Crohn's disease, granulomas, tumors, and fungal and HIV infections.
openaire   +2 more sources